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HIV rapid risk assessment
‘There is a continuous need to keep public health 
and sufficient preventive services on the agenda in 
challenging economic times’. So states an 
EMCDDA–ECDC rapid risk assessment report 
published in January: HIV in injecting drug users in 
the EU/EEA (1). 
In 2011, Greece and Romania witnessed 
a significant increase in HIV case reports and 
prevalence among injecting drug users (see 2011 
Annual report). On 15 November, the European 
Commission called on the agencies to conduct 
a joint rapid enquiry, among their HIV surveillance 
and drug focal points, into whether such increases 
had also occurred elsewhere.
The assessment, undertaken on 29 November, 
revealed that most European countries reported no 
changes in the rate of newly diagnosed cases of HIV 
or HIV prevalence in injecting drug users in 
2010/2011. Six countries, however, documented 
slight increases, while others reported rises in injecting 
risk behaviour or low coverage of prevention services 
among IDUs. Combined, these factors may indicate 
a risk for increased HIV transmission and future 
outbreaks. The report concludes: ‘These countries 
would benefit from critically reviewing their national 
prevention and control programmes’. 
From 25–27 January, the EMCDDA hosted 
a workshop on regional HIV monitoring, organised by 
ECDC and international partners (UNAIDS, WHO). 
This aimed to provide countries with technical support 
for monitoring their HIV responses and reporting 
progress to regional and international bodies. 
The EMCDDA will contribute to the reporting exercise 
with drug-related data from the Reitox network in 
a move to reduce countries’ reporting burden. 
(1) www.emcdda.europa.eu/publications/joint-publications/hiv-in-
injecting-drug-users-2011 
Increased capacity and sophistication in the illicit 
amphetamine market are among the developments 
reviewed in the latest EMCDDA–Europol analysis 
Amphetamine: a European Union perspective in the 
global context (1). Published on 15 December, the 
report describes changing patterns and trends in the 
production and trafficking of this widely used 
synthetic stimulant as well as the chemicals used in 
its manufacture. The report looks at the people and 
organisations involved and the scale of the problem 
in a global context. 
According to the report, amphetamine can be termed 
a ‘European drug’, with data suggesting Europe to be 
the world’s number one producer of the substance 
and a major consumer market. While, globally, 
methamphetamine is more widely used, amphetamine 
has stabilised as the most widely consumed stimulant 
drug in Europe today after cocaine. And in many 
countries, especially in the north and east of Europe, 
it is the second most widely used illicit drug after 
cannabis. This suggests that, although the drug 
attracts much less attention in the media and policy 
circles than cannabis, cocaine or heroin, it should not 
be treated as a ‘secondary issue’. 
Around 12.5 million Europeans have used 
amphetamines in their lifetime, some 2 million having 
used it in the last year. European amphetamine 
markets are therefore ‘highly profitable business 
opportunities’ for organised crime, states the report. 
Distinct production and trafficking areas (‘criminal 
hubs’) are outlined in the study. Large-scale 
production and organised crime involvement are 
found mainly in northern Europe, notably in the 
‘north-west criminal hub’ (centred on the Netherlands 
and to a lesser extent Belgium), where there are 
signs of increased yield and professionalism. 
Significant production and trafficking of the drug 
also occurs in the ‘north-east hub’, notably in Poland, 
where production is reported to be on the rise. 
Meanwhile, the south-east hub (Bulgaria, Turkey) is 
thought to be the main source of ‘captagon’, 
although there are signs that manufacturing could be 
relocating closer to established consumer markets for 
this product in the Near and Middle East.
Commenting, EMCDDA Director Wolfgang Götz 
said: ‘Amphetamine is a drug warranting careful 
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New psychoactive substances
Range of tools needed to counter threat of emerging drugs
‘The speed at which new psychoactive 
substances can appear and be distributed now 
challenges the established procedure of passing 
legislation to control a substance in each country’. 
This is according to Responding to new 
psychoactive substances, the latest EMCDDA 
Drugs in focus briefing launched on 
14 December (1). The briefing describes how 
policymakers are demanding ‘new, faster and 
effective ways of drug control’ that will protect 
public health and deter suppliers from 
circumventing controls. It notes that drug laws are 
not the only means available to meet the 
challenges posed by these substances.
New psychoactive substances are defined as 
narcotic or psychotropic drugs that are not 
controlled by United Nations Conventions, but 
which may pose a public health threat 
comparable to that posed by controlled drugs. 
The briefing describes some of the practical and 
legal obstacles facing Member States when 
responding to such new substances. Testing 
products can be time-consuming and expensive 
which can hinder timely and targeted responses 
by legislators. New drugs may pose health and 
other risks to individuals and the general public, 
yet hard data on these may initially be lacking. 
Legislative procedures to bring a substance 
under the control of the drug law can take 
over a year in some countries. And controlling 
a substance may have unintended consequences, 
such as the emergence of a more harmful, non-
controlled replacement. 
‘Member States require the capacity to rapidly 
identify and scientifically evaluate the 
increasingly diverse and complex new 
substances appearing on the market,’ said 
EMCDDA Director Wolfgang Götz. ‘Their 
response mechanisms should be optimised to 
act effectively and efficiently to protect public 
health with the minimum adverse 
consequences; control under drug law is one 
of various options that can achieve this’.
Underlined in the briefing is the importance 
of national early-warning systems in detecting 
and identifying new substances as the first 
step towards assessing the risks of, and 
ultimately controlling, potentially dangerous new 
drugs. National risk-assessment systems are 
described as lending key support to the 
legislative process by sending ‘accurate 
and credible messages’ to the public about 
potential threats. 
The briefing illustrates how faster processes have 
been introduced in some countries to overcome 
procedural delays in placing a new drug under 
control. These include establishing emergency 
systems, that enable a substance to be 
placed under temporary controls, or fast-track 
systems placing substances under permanent 
control by shortening the consultation periods 
in the law-making process.
‘Speed of reaction may be more important 
than severity’, states the briefing. Existing laws 
in areas such as consumer protection or 
medicines might also be considered as 
options and have already been used to stop 
the open distribution of new drugs. 
Speed of reaction may be more 
important than severity
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‘Striking the right balance between swiftness 
of response to new substances, on the one 
hand, and sufficient scientific evidence and 
legislative supervision, on the other, is an 
important policy goal’, it concludes. 
Looking to the future, the European 
Commission, in cooperation with EU Member 
States, the EMCDDA and Europol, is working 
on new legislation to better address the 
control of new psychoactive substances 
throughout the EU. 
Brendan Hughes
(1) Drugs in focus No 22, available in 25 languages at  
www.emcdda.europa.eu/publications/drugs-in-focus
Second international forum on new drugs ReDNet–EMCDDA 
conference 
The ‘Ever-changing world of psychoactive 
drugs’ is the focus of an international 
conference to take place in Budapest from 
12–13 March (1). The event is an initiative of 
the EU-funded Recreational Drugs European 
Network (ReDNet) project and the 
EMCDDA. This conference will offer an 
opportunity to share scientific knowledge 
on the nature of new compounds and the 
clinical and legal challenges faced by 
multidisciplinary professionals today. 
(1) For more, see: www.rednetproject.eu/conference/
The EMCDDA and the United States National 
Institute on Drug Abuse (NIDA) are joining forces 
to host the Second international forum on new and 
emerging psychoactive substances, to be held in 
Palm Springs (CA) from 8–9 June (1). The rapid 
emergence of new drugs and the global nature of 
the phenomenon highlight the importance of 
international cooperation in this area.
The First international multidisciplinary forum on 
new drugs, organised by the EMCDDA in May 
2011, gathered experts from a wide range of 
disciplines to review global developments in the 
new drugs and ‘legal high’ phenomenon. 
Participants from 40 nations discussed how 
a broad range of new drugs had begun to be 
used in their countries and how policies had been 
developed in response (2). This year’s forum will 
focus on new and emerging synthetic and natural 
drugs, such as synthetic cannabinoid receptor 
agonists (e.g. Spice) and stimulants (e.g. 
cathinones). It will be held in conjunction with 
the 74th NIDA annual meeting.
Liesbeth Vandam and Roumen Sedefov
(1) 2012 NIDA international forum http://international.
drugabuse.gov/
(2) See conclusions at www.emcdda.europa.eu/
news/2011/new-drugs-forum-conclusion and www.emcdda.
europa.eu/publications/drugnet/online/2011/75/article8
3Responses
First European quality standards to improve drug 
prevention in the EU
‘Prevention’ is one of the first issues to be 
mentioned in the public debate on drugs, but 
evidence of what works in practice to prevent 
drug use is often overlooked. On 9 December, 
the EMCDDA launched the first European ‘how 
to’ guide on conducting high-quality drug 
prevention. Entitled European drug prevention 
quality standards: a manual for prevention 
professionals, it was presented at the 
2nd International Conference of the European 
Society for Prevention Research (EUSPR), hosted 
by the EMCDDA in Lisbon (1).
Developing and implementing best practice in 
drug prevention in Europe are goals set by the 
current EU drug strategy and action plan. In line 
with these goals, the manual is the culmination of 
a two-year project to assess existing guidance in 
this area and to meet the need for a commonly 
agreed European framework to improve drug 
prevention in the EU. 
With support from the European Commission, 
the project is the fruit of collaboration between 
the seven organisations of the ‘Prevention 
Standards Partnership’, working closely with 
the EMCDDA (2). Bridging science, policy and 
practice, over 400 international, European 
and national experts and stakeholders 
contributed to developing the standards via 
a dynamic process involving focus groups, 
consultations and studies. 
EMCDDA Director Wolfgang Götz said: 
‘The new manual summarises current 
evidence on how to conduct good drug 
prevention in the EU. The aim of the quality 
standards is not to standardise prevention 
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New manual summarises current 
evidence on how to conduct good 
drug prevention in the EU
practice across Europe, but rather to achieve 
a similar level of high quality, while 
acknowledging diversity of practice’. 
‘Implementing prevention measures correctly with 
evidence-based components will help ensure 
effectiveness and efficiency of funding and 
avoid unintended harmful effects’, he adds. 
‘The manual will provide valuable guidance 
in this respect and allow preventive 
interventions to reach their full potential’.
Gregor Burkhart
(1) For more, see www.emcdda.europa.eu/news/2011/10 
and www.emcdda.europa.eu/news/2011/11
(2) See project website www.cph.org.uk/drugprevention
Best practice portal: 
bridging the gap
One of the added values of the EMCDDA’s 
Best practice portal is the synthesis of 
available evidence on the effects of drug 
demand reduction interventions. Having 
developed a systematic process for updating 
and grading the quality of evidence in the 
portal, the EMCDDA will take another step 
forward in 2012, with a new project to 
identify knowledge gaps and highlight topics 
for further investigation in this area. 
This ‘gap-analysis project’ will proactively 
garner unanswered questions arising from the 
day-to-day experiences of decision-makers, 
practitioners and clients. It will also identify 
topics for the development of guidelines. 
The project, which is now in its protocol 
phase, encompasses a literature review and 
exploratory interviews with individual 
practitioners and clients from across Europe. 
The project will result in a structured overview 
of available information and 
recommendations for bridging the identified 
gaps. Preliminary results will be presented to 
the EMCDDA Scientific Committee in May.
Marina Davoli and Marica Ferri 
(bestpractice@emcdda.europa.eu)
EUFAS visit to EMCDDA
Professor Karl Mann, President of the European 
Federation of Addiction Societies (EUFAS), 
visited the EMCDDA in December to discuss 
with Director Wolfgang Götz the potential for 
future collaboration between the two bodies. 
The EMCDDA and EUFAS share a number of 
interests with regard to treatment and prevention, 
best practice and addiction research (1). Areas 
of possible coordination and mutual assistance 
will now be drawn up for further consideration. 
The EMCDDA will participate in the third EUFAS 
annual meeting to be held this autumn in Berlin.
Roland Simon 
(1) For more, see www.eufas.net
EMCDDA–WCO cooperation
‘We are facing a growing challenge to the way 
we protect our citizens from drug trafficking and 
the collateral damage that it brings with it’, said 
EMCDDA Director Wolfgang Götz in Brussels 
on 25 January on the eve of International 
Customs Day (1). Addressing participants at the 
opening of the World Customs Organization’s 
‘Global forum on combating illicit drug trafficking 
and related threats’, he spoke of the ‘many 
opportunities’ but also the ‘new threats’ brought 
by our modern joined-up world. ‘Drug trafficking 
and the trafficking of precursor chemicals, 
together with the related issues of money 
laundering and corruption, are foremost amongst 
these’, he said. The EMCDDA contributed to the 
debate with a presentation entitled: ‘The patterns 
of supply and demand for narcotics are 
constantly evolving, requiring sustained 
monitoring and dynamic responses in Europe’.
(1) For more, see www.emcdda.europa.eu/news/2012/
speeches/WCO and  
www.emcdda.europa.eu/about/partners/wco
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Drugs and drug 
policy is a recent 
edition in the ‘What 
everyone needs to 
know’ series from 
Oxford University 
Press. Written by 
three noted authorities on the subject, the 
book opens by defining ‘drugs’, exploring 
how they work on the brain, discussing the 
nature of addiction and examining the 
damage they do to users. The book then 
moves on to policy, answering questions on 
legalisation, the role of criminal prohibitions 
and the relative legal tolerance for alcohol 
and tobacco. 
In further sections, the authors dissect the 
illicit drug trade, from street dealers to 
kingpins, and show the precise nature of the 
relationship between drugs and crime. 
They also examine treatment and discuss the 
beneficial effects of some abusable 
substances. Finally, the book pans outward, 
looking at the role of drugs in foreign policy 
and their relationship to terrorism. 
Written in the form of a question-and-answer 
guidebook, the work provides an up-to-date 
overview of the subject.
Authors: Kleiman, M.A.R., Caulkins, J.P., 
Hawken, A. 
Publisher: Oxford University Press, New York
Language: English 
Date: June 2011
ISBN 13: 978-01-9976-451-8
ISBN 10: 0199764514
Price: USD 16.95 (paperback)
Ordering information:  
www.oup.com/us/catalog/general/series
The EMCDDA is responsible for the selection 
of materials for the Bookshelf and for the text 
presented. However, responsibility for the content 
of these materials and the opinions expressed 
therein lies with the authors themselves.
Bookshelf
Drugs and drug policy
What everyone needs to know
2012 work programme
New developmental areas supplement core analysis
The EMCDDA’s 2012 work programme, 
adopted by the Management Board in 
December 2011, is designed to achieve 
two objectives. On the one hand, it seeks 
to ensure delivery on commitments detailed 
in the agency’s three-year strategy and 
work plan (2010–12). On the other, it 
helps lay sound foundations for the agency 
to meet the challenges of the next triennial 
period (2013–15). 2012 is therefore an 
important year for both planning and 
substantive activities.
The work programme is structured around 
seven substantive areas aimed at 
monitoring and reporting on the drugs 
problem in Europe. A number of new 
developmental areas have also been 
introduced this year, supplementing the core 
analysis provided through the EMCDDA’s 
annual reporting exercise. These include the 
further development of cross-indicator 
analysis and the exploration of potential 
new data sources on drug treatment and 
harm reduction. Also proposed is the 
analysis of existing information on 
prevention services for minorities.  
In 2012, particular attention will be paid 
to the further improvement of quality 
assurance mechanisms related to data 
collection and analysis. Also, a new key 
indicator assessment will be carried out to 
evaluate progress and support further 
methodological developments. To ensure 
a better understanding of the availability, 
accessibility and quality of responses to 
drug use in Europe, several thematic 
publications will be released. 
Technical work started in 2010 (in close 
cooperation with the European 
Commission) to develop European key 
indicators in the area of drug supply and 
supply reduction will reach a final stage in 
2012 with the joint organisation of the 
second European conference on supply 
indicators. This event should allow 
a consensus to be reached at European 
level on key indicators to be developed 
and implemented from 2013 onwards. 
In 2012, attention will be paid to 
the further improvement of quality 
assurance mechanisms related to 
data collection and analysis
2012 — an important year for 
both planning and substantive 
activities
Another priority for 2012 will be the ongoing 
implementation of the European early-warning 
system on new psychoactive substances and 
its supporting database and tools. 
One important aspect is the further scaling-up 
of activities that will improve Europe’s 
capacity to monitor and evaluate drug 
policies. Work in this area will be structured 
around three linked themes: the legal basis for 
drug policies and how laws are implemented; 
monitoring policy development and 
supporting policy evaluation; and 
understanding better the economic aspects of 
European drug policies. 
Finally, in the area of governance, a central 
activity will be the development of the next 
three-year strategy and work programme 
(2013–15). To be considered in this exercise 
will be the findings of the external evaluation 
of the agency (due in April 2012), as well as 
the implications of the future policy framework 
that will supersede the current EU drug strategy 
and its action plans. The Management Board 
adopted a total budget of EUR 16 065 709 
for the EMCDDA in 2012.
Monika Blum and Narcisa Murgea
Available in English at:  
www.emcdda.europa.eu/work-programmes/2012
(see also page 7).
5Drugs-Lex  
Romania passes law to curb distribution of new psychoactive substances
Laws which make distributing or 
advertising new psychoactive substances 
a criminal offence have been passed in 
a number of European countries in recent 
years (e.g. Ireland and Poland in 2010). 
Meanwhile, other Member States (e.g. 
Italy, Finland) have used existing consumer 
safety or medicines legislation to prevent 
their open sale. 
In February 2011, as a rapid response, 
a Romanian government order set up 
multidisciplinary teams to target environments 
where ‘harmful unregulated psychoactive 
substances’ were being distributed or 
consumed (1). Bringing together 
representatives from ministries (e.g. health, 
interior, agriculture) and health and 
consumer protection agencies, the group 
was tasked to enforce all existing laws in 
their respective fields to stem the 
distribution of these substances. 
These included health laws banning 
smoking in public places and consumer 
safety laws prohibiting the inaccurate 
labelling of products. The government 
order also foresaw a law that would better 
define the substances detected and grant 
the authorities more legislative power to 
control them.
Responding to the continued rise in the 
consumption of new psychoactive substances, 
Romania passed this expected law at the end 
of 2011. Under this law, a specific permit is 
required to sell any product likely to provoke 
psychoactive effects similar to those 
caused by substances controlled under 
drug laws (2). These effects are defined as 
those provoking ‘changes in functions and 
mental processes and behaviour’, or 
‘causing dependency’. Unlike the earlier 
government order, the new law makes no 
specific reference to ‘harmful’ substances.
Under the new legislation, the distribution of an 
unregulated psychoactive substance without 
a permit (particularly if consumption was likely), 
could result in 1–3 years in prison when the 
psychoactive effects are unknown but likely. 
The sentence increases to 2–8 years when 
the psychoactive effects are known. 
Advertising the psychoactive effects of the 
substance is punishable by 1–3 years in 
prison. Claiming that the products are lawful 
is punishable by 3–10 years, perhaps in 
response to the popular misnomer ‘legal 
highs’. There is no penalty for the possession 
of these substances for the purpose of use.
Brendan Hughes and Bogdan Iasnic
(1) Government order of 16 February 2011  
www.dreptonline.ro/monitorul_oficial/monitor_oficial.
php?id_monitor=8243
(2) Law 194/2011 of 10 November 2011 
www.dreptonline.ro/legislatie/legea_194_2011_combaterea_
operatiunilor_produse_susceptibile_efecte_psihoactive.php
International Partners
EMCDDA IPA 3 project in Serbia 
A new Country overview, EMCDDA publications in Serbian and 
enhanced stakeholder engagement are among the many outcomes of the 
EMCDDA’s technical assistance project in Serbia, which came to a close 
in November 2011. Serbia was one of eight candidate and potential 
candidate countries to the EU which received EMCDDA assistance under 
a two-year project (IPA 3) to establish national drug information systems in 
line with EU standards (1). Under the project, representatives of EU national 
focal points (NFPs), or ‘Reitox coaches’, assisted ‘national correspondents’ 
in running activities in their country according to EU norms. In the case of 
Serbia, this coaching function was carried out by the Cyprus NFP. 
In the course of IPA 3, seminars organised by the Serbian Ministry of 
Health and supported by the EU looked at ways to strengthen 
cooperation between the EMCDDA and Serbia and explored 
perspectives for setting up a national drug information system. In 2011, 
Serbian experts participated in Reitox training activities, while a Serbian 
study visit to the Cyprus NFP offered key insights into the functioning of 
a Reitox focal point. By the end of the project, 1 000 Serbian 
prevention and treatment experts had been informed on the importance 
of cooperation with the EMCDDA. At the IPA 3 closing seminar in 
Brussels in October, national representatives presented the country’s 
drug situation and methodological advances.
Biljana Kilibarda, IPA 3 national correspondent for Serbia 
Neoklis Georgiades, Reitox coach, Cyprus NFP
(1) http://ec.europa.eu/enlargement/how-does-it-work/financial-assistance/instrument-
pre-accession_en.htm
Enhancing EMCDDA–ESPAD cooperation
The EMCDDA and the European School Survey Project on Alcohol and 
Other Drugs (ESPAD) are scaling up their cooperation in monitoring 
substance use among 15- to 16-year-old school students. Their commitment 
was underlined in a joint statement adopted at the 2011 ESPAD project 
meeting, hosted by the EMCDDA in Lisbon (27–29 November) (1).
ESPAD data provide crucial information on substance use among school 
students of this age and are routinely included in the EMCDDA’s annual 
reporting on the drug situation in Europe. In the statement, the 
partners agreed to boost technical cooperation to enhance 
understanding of long-term drug use trends in Europe. 
Cooperation between the EMCDDA and ESPAD began in the mid-1990s 
and was formalised by a ‘cooperation framework’ agreed in 2007. 
Based on the encouraging experiences to date, the two partners 
reaffirmed in November the long-term value to be achieved through close 
collaboration and the sharing of expertise. Among others, they agreed to: 
develop an enhanced dissemination strategy for ESPAD findings and 
work together to ensure harmonisation of methods and support 
methodological developments. In 2012, the partners will be 
collaborating, for the second time, in a joint multilingual publishing project 
to disseminate the key results of the latest ESPAD survey (2011). This 
summary, in 23 languages, is scheduled to be released before summer. 
Deborah Olszewski
(1) See joint statement at www.emcdda.europa.eu/about/partners/espad and 
Fact sheet at www.emcdda.europa.eu/news/2011/fs-6
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Spotlight
European summer school 
on illicit drugs
Wastewater analysis
EMCDDA launches new multicity project
Cooperation with CICAD
The EMCDDA has recently launched 
a multicity ‘demonstration project’ to 
investigate the potential of wastewater 
analysis as an indicator for estimating 
community drug use levels. By the end of 
2012, the project will have generated 
comparable data from at least 15 European 
cities, thanks to an agreed common sampling 
approach designed to ensure maximum 
comparability. The project partners met in 
Lisbon on 19 January to establish a project 
work plan and key deliverables (1). 
By sampling a known source of 
wastewater — for example, a sewage 
influent to a wastewater treatment plant — 
scientists can now obtain estimates of the total 
quantity of drugs consumed by a community 
by measuring the levels of illicit drug 
metabolites excreted in urine (2). This 
demonstration project will provide 
comparable information in real time on 
weekly patterns of use, trends and changing 
consumption habits in the participating cities. 
Wastewater analysis is an emerging science. 
While its methods do not provide the type of 
detailed consumption data currently yielded by 
drug surveys, its ability to provide timely estimates 
of illicit drug consumption in a given population 
make it a useful complement to existing methods 
for studying drug use trends in Europe.
Liesbeth Vandam and Ana Gallegos
(1) The project is being undertaken by a consortium of 
researchers from over 10 European countries.
(2) For more, see www.emcdda.europa.eu/wastewater-analysis
Student drug use in the Caribbean
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The Lisbon-based Instituto Superior das 
Ciências do Trabalho e da Empresa (ISCTE) 
and the EMCDDA are currently 
collaborating on a summer school 
programme entitled: ‘Illicit drugs in Europe: 
supply, demand and public policies’. 
Registration opened on 15 December for 
the course, which will take place in Lisbon 
from 2–13 July.
During the two-week programme, EMCDDA 
scientific experts, ISCTE-professors and 
policymakers will prepare participants to 
meet the complex policy challenges in this 
field. They will do so via a multidisciplinary 
and inclusive approach to the study of the 
drugs problem, both in Europe and beyond. 
Week 1 of the summer school focuses on 
‘Defining the problems’ and will feature 
lectures on ‘Problem drug use in Europe’, 
‘Drug supply in Europe’ and ‘Detecting new 
drugs’. Week 2 explores ‘Understanding drug 
policies and interventions’ with lectures on 
‘(Inter)national drug policies’, ‘Prison health’, 
‘Preventing drug use’ and ‘Harm reduction’.
The target audiences for the summer school 
are university students (undergraduate and 
graduate), researchers, professionals and 
administrators interested or working in the 
drugs field. ECTS credits will be given for 
the courses and students can transfer credits 
to other European universities using the 
ECTS-system.
Further information on the summer school 
programme, fees and location is available 
at www.drugsummerschool.cies.iscte-iul.pt
Registration, Phase 1: 15 December–15 March 
(discount); Phase II: 15 March–15 June.  
See Fact sheet at  
www.emcdda.europa.eu/news/2011/fs-7
The latest data on drug use among 
secondary school students in 12 Caribbean 
countries has recently been published by the 
Inter-American Observatory on Drugs (OID) (1). 
The report, launched at the fourth biennial 
meeting of Caribbean Drug Observatories in 
Port of Spain (2011), offers a comprehensive, 
regional analysis of drug use in this group. 
The findings demonstrate that, although the 
participating nations share similar histories and 
cultures, the dimensions of drug use are quite 
unique to each country. While alcohol and 
marijuana are the main drugs of use, patterns 
still vary widely from country to country. 
Compared to other regions, the prevalence of 
marijuana use in the school population in the 
Caribbean is high, and in some countries, 
higher than that of tobacco use.
The biennial meeting was hosted by 
the Organisation of American States (OAS), 
the Inter-American Drug Abuse Control 
Commission (CICAD) and the Government of 
Trinidad and Tobago (2). The EMCDDA 
participated in the event, providing 
a refresher course on how to build a national 
drug observatory and set up a drug 
information system. Key topics from the 
EMCDDA and CICAD–OAS joint handbook 
Building a national drugs observatory were 
illustrated via examples of collaboration 
between the EMCDDA and the Reitox 
network and the European experience in 
data collection on drugs.
Sandrine Sleiman
(1) The OID is CICAD’s statistical, information and 
scientific research branch www.cicad.oas.org/oid 
Report available at www.cicad.oas.org/Main/pubs/
StudentDrugUse-Caribbean2011.pdf 
(2) www.cicad.oas.org/oid/caribbean/2011/Report%20
2011%20Obs%20Meeting.pdf
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Wastewater analysis: a useful 
complement to existing methods for 
studying drug use trends in Europe
In some countries, marijuana use is 
more prevalent than tobacco use
7The EMCDDA’s 2012 work programme takes forward activities 
begun in 2010 to implement the EMCDDA’s three-year strategy 
(2010–12). This strategy seeks to: consolidate and deepen the 
analysis of core data sets held at the EMCDDA; invest in more 
complex and policy-relevant analysis; and develop a small 
number of new areas of strategic importance. Now available 
online, this year’s work programme sets out the agency’s 
specific objectives accompanied by their related activities and 
expected outcomes. This new structure is the result of the 
ongoing rationalisation of planning processes and procedures 
taking place at the EMCDDA.
Available in English at www.emcdda.europa.eu/work-programmes/2012
Kratom added to online ‘drug profiles’
The EMCDDA released in February the latest in its series of online drug profiles. The new 
profile is of kratom, the name given to tree and leaf preparations of the South-east Asian 
tree Mitragyna speciosa. The main psychoactive components in the leaves are mitragynine 
and 7-hydroxymitragynine. Traditionally, the leaves are chewed or made into tea but are 
seldom smoked. At a low dose, kratom has stimulant effects and is used to combat fatigue 
during long working hours. At high dosages, it can have sedative-narcotic effects. 
Kratom is used in traditional medicine and as an opium substitute. It was the most 
commonly found substance sold through online new drugs/’legal highs’ shops in an 
EMCDDA assessment (‘snapshot’) carried out in July 2011.
Drug profiles in German, English and French at www.emcdda.europa.eu/publications/drug-profiles (see Online 
snapshot at www.emcdda.europa.eu/publications/scientific-studies/2011/snapshot).
Resources
Events and materials  
on the drugs issue
HIV in Europe 
‘Working together for 
optimal testing and earlier 
care’, is the focus of the third 
‘HIV in Europe’ conference to 
be held in Copenhagen from 
19–20 March. ‘HIV in Europe’ is a pan-European 
initiative launched in 2007 to inform processes, 
share knowledge and improve the evidence base 
around important issues of earlier testing and care 
in relation to HIV. The event, which will gather 
around 300 European stakeholders, will include 
discussions on the implementation of European 
and national testing guidelines.
For more, see www.hiveurope.eu 
ISSDP annual conference
The sixth annual conference of the International 
Society for the Study of Drug Policy (ISSDP) will 
take place in Canterbury (UK) from 30–31 May. 
The event, hosted by the University of Kent, will 
discuss a wide range of drug policy issues, with 
a particular focus on: ‘How can and do empirical 
studies influence drug policy?’. A plenary session 
will be devoted to discussions on the report of the 
Global Commission on Drug Policy. 
For more, see www.issdp.org/conferences.php
International AIDS conference
‘Turning the tide together’ is the title of the XIX 
International AIDS conference to take place in 
Washington DC from 22–27 July 2012. 
The AIDS 2012 programme will present new 
scientific knowledge and offer opportunities for 
structured dialogue on the major issues facing the 
global response to HIV. The event will include 
a variety of session types, from abstract-driven 
presentations to symposia, bridging and plenary 
sessions. Other related activities include a ‘Global 
village’, satellite meetings, exhibitions and 
affiliated independent events.
For more, see www.aids2012.org
Organisations wishing to publicise their newsletters, 
magazines, websites, CD-ROMs or any other 
resources are invited to contact  
Kathryn.Robertson@emcdda.europa.eu
Products and services
EMCDDA work programme 2012
New Insights on heroin-assisted  
treatment — coming soon
Supervised injectable heroin (SIH) treatment has emerged over 
the last 15 years as a potentially important second-line 
treatment for entrenched heroin addicts for whom previous 
orthodox treatments (i.e. oral methadone maintenance 
treatment or residential rehabilitation) have produced little 
benefit. This treatment, by its very nature, attracts attention and 
controversy. The EMCDDA examines the evidence base for the 
effectiveness of this treatment in an upcoming edition in its 
Insights series: New heroin-assisted treatment: recent evidence 
and current practices of supervised injectable heroin treatment 
in Europe and beyond. The publication will offer a historical 
overview of SIH, including related international policy and 
legislation, before moving on to examine the research evidence and clinical and policy 
experience with this new treatment.
Available in English at www.emcdda.europa.eu/publications/insights
Thematic paper on ‘drug mules’ — coming soon
The latest EMCDDA thematic paper aims to determine whether a common definition of 
‘drug mules’ can be developed in the European context. The implications of this for data 
gathering and future research are assessed in the document. 
Available in English at www.emcdda.europa.eu/publications/thematic-papers
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EMCDDA meetings
25–27 January:  Workshop on global and regional HIV 
monitoring, ECDC/EMCDDA, Lisbon (ecdc.
europa.eu/en/press/events/Pages/Events.aspx).
22–23 February:  Reitox Academy on ‘Residential treatment for 
drug users in Europe’, Lisbon. 
12–13 March:  International conference ‘The ever-changing 
world of psychoactive drugs’, ReDNet/
EMCDDA, Budapest (www.rednetproject.eu/
conference).
24 April:  EMCDDA expert meeting ‘Monitoring the uptake 
of HCV treatment among IDUs in Europe’, Lisbon.
External meetings
9 February:  Heads of EU agencies meeting, coordination 
of the agencies, Brussels.
9–10 February:  ESPAD steering group meeting, Stockholm  
(www.espad.org).
16 February:  3rd Ministerial conference of the Paris Pact 
on combating the Afghan illicit opiate trade, 
UNODC, Vienna (www.unis.unvienna.org/
unis/en/pressrels/2012/unisinf436.html).
7–9 March:  EFCAP Congress 2012, Berlin (www.efcap2012.de).
12–16 March:  Fifty-fifth session of the Commission on 
Narcotic Drugs, Vienna (www.unodc.org/
unodc/en/commissions/CND).
19–20 March:  ‘HIV in Europe’ conference, Panum Institute, 
Copenhagen (www.hiveurope.eu).
27–29 March:  New methodology tools for policy and 
programme evaluation, University Rome Tor 
Vergata, Rome.
EU meetings
6 February:  Horizontal working party on drugs, Brussels. 
5 March:  Horizontal working party on drugs, Brussels. 
6 March:  EU–LAC technical meeting, Brussels.
18 April:  Horizontal working party on drugs, Brussels. 
19 April:  EU–LAC technical meeting, Brussels.
attention, despite the fact that its use has remained relatively stable in 
most European countries over the past decade. With this publication, we 
hope to enhance the understanding of an often overlooked, but 
nevertheless key, component of the European scene for stimulant drugs’. 
Amphetamine can be produced at relatively low cost, close to consumer 
markets. More problematic for the illicit producer, however, is obtaining the 
precursor chemicals required to manufacture the drug (e.g. BMK). The report 
notes how increasingly effective international efforts to control the trade in 
precursors have prompted some illicit manufacturers to bypass regulations by 
synthesising, rather than purchasing, precursors from so-called ‘pre-
precursors’, or by masking them as other non-controlled chemicals before 
importation. Seizures of the pre-precursor phenylacetic acid (a precursor of 
BMK), rose sharply in 2009, with a total of almost 42 tonnes confiscated 
worldwide (160 kg in 2008). While amphetamine is often seen as a ‘poor 
man’s cocaine’, being the cheaper of the two drugs, the lower price in times 
of recession could increase its appeal to potential users. 
‘This joint report comes as a strong reminder of the growing threat posed 
by synthetic drugs’, said Cecilia Malmström, EU Commissioner for Home 
Affairs. ‘A better understanding of the amphetamines market — 
production, trafficking and use — seems crucial for a more effective and 
intelligent policy response’.
Laurent Laniel
(1) See news release at www.emcdda.europa.eu/news/2011/13
Continued from page 1
EMCDDA–Europol amphetamine review
Statutory bodies
Quality of EMCDDA outputs commended
The EMCDDA’s continued commitment to improving the level and quality 
of its scientific outputs was commended by the agency’s Scientific 
Committee which met in Lisbon from 14–15 November. At the meeting, 
the Committee endorsed the EMCDDA’s 2012 work programme, 
welcoming its references to improved planning and risk-management 
processes in the light of the current economic climate.
The role of the EMCDDA in promoting research and monitoring in Europe 
was also discussed at the meeting, as was the ongoing external 
evaluation of the agency being undertaken by the Centre for Strategy 
and Evaluation Services (UK). In the margins of the meeting, and on the 
eve of the 2011 Annual report launch (14 November), the EMCDDA and 
Scientific Committee hosted the 2011 EMCDDA Scientific paper award. 
Five scientific papers judged to enhance understanding of the European 
drugs problem were acclaimed at this inaugural event.
Maria Moreira
